Peer-influenced content. Sources you trust. No registration required. This is HCN.
Annals of Internal Medicine
In a 794-patient randomized trial, early-stage type 2 diabetes patients uncontrolled on metformin who received tirzepatide achieved nearly twice the HbA1c reduction of those on intensified conventional care at 2 years, and 60% reached normoglycemia (HbA1c <5.7%), compared to 24% in the ICC arm.
Cardiology June 8th 2026
Healthline
Phase 3 TRIUMPH-1 trial results for retatrutide, a triple hormone agonist targeting GIP, GLP-1, and glucagon receptors, showed up to 28.3% mean weight loss at 80 weeks and 30.3% in patients with BMI ≥35 at 104 weeks — the largest weight reduction reported in a medication trial to date, per Lilly’s press release.
MDLinx
Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.
Cardiology June 2nd 2026
Medical Xpress
An observational study of 17,088 UK Biobank participants found that substantial cardiovascular risk reduction required 560–610 minutes of moderate to vigorous physical activity per week, roughly three to four times current public health recommendations.
Medical Professionals Reference (MPR)
The FDA approved baxdrostat (Baxfendy), a selective oral aldosterone synthase inhibitor, as an adjunctive treatment for adults with hypertension uncontrolled on at least two existing antihypertensive agents, including a diuretic.
Conexiant
A Senate investigative report alleged that federal health officials received early signals of myocarditis and pericarditis following mRNA COVID-19 vaccination in adolescents and young adults months before public advisories were issued, citing internal agency communications and subpoenaed HHS documents.